Unlock instant, AI-driven research and patent intelligence for your innovation.

Vaccine against intra-cellular pathogens

A pathogen and vaccine technology, applied in the direction of antibody medical components, bacterial antigen components, protozoan antigen components, etc., can solve problems that have not yet been prompted and improve the intracellular level of HSPs

Inactive Publication Date: 2002-09-18
IMMUNOBIOLOGY LTD
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] However, treatment of cells with heat shock or other stresses has not been suggested to increase the intracellular levels of HSPs
This may be because it needs to stimulate only one subtype of HSPs, especially the immunogenic subtype, and currently there is no way to specifically stimulate cells to produce this subtype of HSPs with enhanced immunogenicity.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vaccine against intra-cellular pathogens
  • Vaccine against intra-cellular pathogens
  • Vaccine against intra-cellular pathogens

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Example 1: Preparation of heat-induced SPs

[0035] Cells infected with M. bovis were washed in a serum-free medium such as RPMI (Sigma), then heat-shocked at 45°C for 0.5 hours, or at 42°C for 5 hours, and incubated overnight. Cells were then washed in serum-free medium followed by phosphate buffered saline (PBS). Cells were resuspended in homogenization buffer. This homogenization buffer can be a hypotonic buffer, such as containing 2mM MgCl 2 10mM phosphate, pH7.4. Cells are then disrupted with a cell homogenizer (eg Dounce or Potter homogenizer, Ultraturrax or Waring mixer). Alternatively, the homogenization buffer may contain a detergent, such as PBS with 0.5% Tween, at a concentration between 0.1-1%, and suitable for solubilizing cell membranes. Cell lysates are then processed by centrifugation, typically at 3-5000g for 5 minutes to remove nuclei and cell debris, followed by high speed centrifugation at 100000g for 15-30 minutes. The supernatant thus obtained...

Embodiment 2

[0039] Cell lines infected with Plasmodium are incubated in serum-free medium such as RPMI (Sigma) and incubated with TNF-[alpha] overnight. Typically, rat hepatocytes prepared by collagenase treatment of rat liver tissue were infected with Plasmodium Berghei by incubating rat hepatocytes with three times the number of parasite cells at 35°C for 5 hours. Cells were then incubated overnight with or without TNF-α. TNF-induced and control cells were washed in serum-free medium followed by phosphate-buffered saline (PBS). Example 3: Immunization with induced HSPs; immunity in vaccine recipients

Embodiment 3

[0040] Vaccine compositions containing HSP complexes were prepared as described in Example 1, and mice and rabbits were vaccinated by injecting 1-10 μg of stress protein-containing extracts in phosphate buffered saline, after an initial injection of one Booster with the same dose of vaccine 1 month later. Immunity induced by pathogens was analyzed by Western blot using total Plasmodium or M. bovis proteins. Antibody titers of 1:1-10000 are usually obtained, and cytotoxic T cell activity against pathogen-infected cells can also be detected in immunized mice. Challenge with immobilized Plasmodium or M. bovis at 6, 12 and 18 months after primary immunization resulted in good antibody responses with titers ranging from 1:1 to 10,000, indicating a good memory response in immunized animals. Example 4: Comparison of peptides bound in constitutive and induced SP complexes and their use as vaccines

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a method for producing and isolating specific immunogenic heat shock proteins induced by heat or tumour necrosis factor treatment of cells infected by intra-cellular pathogens; and vaccines prepared from such proteins.

Description

[0001] The present invention relates to a vaccine and a method of producing the vaccine. More particularly, the present invention relates to methods for producing vaccines of stress-induced proteins from cells infected with intracellular pathogens, and compositions obtained thereby. Background of the invention [0002] An important component of any human immune response is the presentation of antigens to T cells by antigen presenting cells (APCs) such as macrophages, B cells or dendritic cells. Peptide fragments of exogenous antigens are presented on the surface of macrophages together with major histocompatibility complex (MHC) molecules via association with accessory molecules such as CD4 and CD8 molecules. Such antigenic peptide fragments presented in this manner are recognized by T cell receptors of T cells. Interaction of antigenic peptide fragments with T cell receptors results in proliferation of antigen-specific T cells and secretion of lymphokines by T cells. The na...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/00A61K39/385A61P37/04
CPCA61K39/385A61K2039/52A61K2039/6043A61P31/00A61P31/04A61P33/00A61P33/02A61P37/00A61P37/04Y02A50/30
Inventor 卡米洛·安东尼·利奥·塞尔温·科拉科
Owner IMMUNOBIOLOGY LTD